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REPLY: Predicting Sudden Cardiac Death in Heart Failure
We thank Dr. Weir for the insightful comments in regard to our recent report (1) . We wholeheartedly agree with the assertion that biomarkers may play a role in prediction of risk of sudden cardiac death in combination with electrical and structural assessments of the heart. Cardiomyocytes express BAG3, a protein involved in homeostatic response to mechanical stress; mutations in BAG3 have been implicated in several cardiomyopathies (4). We recently described for the first time an extracellular form of BAG3 released by stressed cardiomyocytes. The protein was identifiable using mass spectroscopy of serum samples from patients with chronic HF (left ventricular ejection fraction <45%); release of BAG3 appeared to trigger an immune response because serum anti-BAG3 antibodies were also measurable in these patients. However, using a specific enzyme-linked immunosorbent assay for measuring BAG3 protein concentration in serum samples, we could not detect significant differences between BAG3 values in healthy subjects and patients with HF using New York Heart Association (NYHA) functional class I to III symptom severity (5) .
In the present analysis, we report that BAG3 protein concentration was significantly higher in serum samples from 20 patients with HF with NYHA functional class IV compared with 44 healthy subjects or 59 patients with NYHA functional class I to III ( Figure 1A ). Differences were greatest (p < 0.001) between healthy controls and patients with NYHA class I versus patients with NYHA class IV and remained quite significant (p < 0.01) when highly symptomatic patients were compared with those with NYHA class II to III symptoms. Notably, high concentrations of BAG3 were associated with death, implantation of a Please note: BIOUNIVERSA s.r.l., which produces anti-BAG3 antibodies, provided them free of charge for this study. Drs. De Marco, D'Auria, Rosati, and Turco are shareholders of BIOUNIVERSA, which provided some of the antibodies. Dr. Januzzi, Jr has received significant grant support from Roche Diagnostics, Siemens, Singulex, and Thermo Fisher; has received significant consulting income from Critical Diagnostics and Sphingotec; and he has participated in clinical endpoint committees and/or data safety monitoring boards for Novartis and Amgen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. in combination with other tests, in monitoring progression of heart failure. We agree that a multiple biomarker approach may add unique diagnostic and prognostic information (2) . In our study, we were not focused on chronic heart failure or long-term outcomes but rather the burden of acute heart failure on our nation's emergency departments. 
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